News

Climb Bio Welcomes Susan Altschuller as CFO to Enhance Leadership

Climb Bio Welcomes Susan Altschuller as CFO to Enhance Leadership

Climb Bio Strengthens Leadership with New CFO

Climb Bio, Inc. (NASDAQ: CLYM), a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, has announced the appointment of Susan Altschuller, Ph.D., MBA, as its new Chief Financial Officer. This strategic hire is set to enhance Climb Bio's leadership team and drive the company's financial strategies forward.

Bringing Extensive Experience to Climb Bio

Dr. Altschuller joins Climb Bio with over 20 years of rich experience in strategic and financial leadership within the biopharmaceutical sector. Her previous role as Chief Financial Officer at Cerevel Therapeutics involved navigating the company through its significant acquisition by AbbVie, a partnership valued at $8.7 billion. Additionally, her tenure at ImmunoGen was marked by support for the company's first commercial launch, highlighting her solid track record in financial execution and operational strategy.

A Proven Biopharmaceutical Leader

In her career, Dr. Altschuller has also held critical positions at Alexion, where she managed investor relations, along with enterprise finance roles at Bioverativ, which is known for its focus on hemophilia treatments. Starting her career as a consultant with the Frankel Group, she has built an impressive portfolio of leadership experiences that are sure to benefit Climb Bio and its mission.

Excitement for Future Developments

Commenting on her new position, Dr. Altschuller expressed enthusiasm for Climb Bio's vision. "I am inspired by the potential of Climb Bio's pipeline to make a significant impact on immune-mediated diseases," she stated. As the company advances its programs, which include budoprutug and CLYM116, her expertise will be pivotal in guiding the financial strategies that will empower Climb Bio as it reaches critical clinical milestones.

Advancing Clinical Pipelines

Climb Bio is currently focused on advancing budoprutug, an anti-CD19 monoclonal antibody that has demonstrated efficacy in depleting B-cells. This therapy has the potential to address various B-cell mediated diseases. Meanwhile, CLYM116 is an anti-APRIL monoclonal antibody being developed specifically for the treatment of IgA nephropathy, and the clinical development of these therapies aligns with Dr. Altschuller's leadership experience.

Equity Award for Dr. Altschuller

In connection with her appointment, Climb Bio has issued an inducement equity award to Dr. Altschuller. This award, established under the company's 2025 Inducement Plan, includes a non-statutory stock option to purchase 600,000 shares of Climb Bio common stock. The exercise price is set at the closing stock price as reported on her start date, reinforcing the company’s commitment to aligning her interests with those of its shareholders.

Commitment to Shareholder Value

Dr. Altschuller's stock option will vest over four years, ensuring her ongoing contribution to the company’s long-term success. She emphasized the importance of creating value for shareholders through the advancement of Climb Bio's promising therapeutic portfolio. This strategic focus on both innovation and fiscal responsibility sets the tone for the company’s trajectory in the biotechnology space.

About Climb Bio, Inc.

Climb Bio is dedicated to developing therapeutics that address severe immune-mediated diseases. Their innovative pipeline, featuring budoprutug and CLYM116, underscores a commitment to offering patients effective treatment options. As the company evolves, it remains focused on patient-centric solutions and scientific advancements in the field of immunology.

Contact and Further Information

For more details or inquiries, interested parties can contact Carlo Tanzi, Ph.D., at Kendall Investor Relations via email at catanzi@kendallir.com. Stay updated on Climb Bio's progress and initiatives as it continues to expand its role in the biopharmaceutical market.

Frequently Asked Questions

Who is the new Chief Financial Officer at Climb Bio?

Susan Altschuller, Ph.D., MBA, has been appointed as the new Chief Financial Officer at Climb Bio.

What experience does Dr. Altschuller bring to Climb Bio?

Dr. Altschuller has over 20 years of experience in financial leadership within the biopharmaceutical industry, including key roles at Cerevel Therapeutics and ImmunoGen.

What are Climb Bio's primary therapeutic focuses?

Climb Bio focuses on developing treatments for immune-mediated diseases, with pipelines that include budoprutug and CLYM116.

How will Dr. Altschuller impact Climb Bio?

Her extensive experience in strategic financial management is expected to significantly contribute to Climb Bio's clinical advancements and financial strategies.

What is the significance of the inducement equity award for Dr. Altschuller?

The inducement equity award aligns Dr. Altschuller’s incentives with the company's performance, ensuring her commitment to enhancing shareholder value.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 36

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 137

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
CVRx Lawsuit Puts a Brutal 59.76% Drop Under Focus

Updated Category News Views 33

Sixty cents on the dollar vanished from CVRx in one trading day, and that kind of wreckage deserves more than a shrug. Shares fell $3.55, or 59.76%, to $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. For holders of NASDAQ:CVRX, the immediate question is not whether the chart looks...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 87

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 7

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon.com Options Insights: Market Sentiment Shifts in Focus

Updated Category News Views 299

Amazon.com Options Insights: Market Sentiment Shifts in Focus Investors are showing a notable optimistic stance towards Amazon.com (NASDAQ: AMZN), and ignoring this momentum would be unwise. Recent insights into options trading reveal significant movements that could signal important changes ahead. Our analysis of options data indicates that a substantial number of trades...

Continue Reading
Global Job Vacancies Decline Amid Economic Uncertainty

Updated Category News Views 278

Global Job Vacancies Experience a Notable Decrease LONDON - A recent survey highlights a decline in white-collar job vacancies worldwide, attributed to various factors such as the U.S. election, uncertainty around tax increases in the U.K., and escalating geopolitical tensions. Insights from the Recruitment Sector The monthly Global Jobs Index released by recruitment...

Continue Reading
Jura Energy Corporation Releases Interim Financial Statements

Updated Category News Views 194

Jura Energy Corporation Announces Interim Filings Release Jura Energy Corporation has announced the filing of its condensed consolidated interim financial statements as of June 30, 2024. This report details the company's financial performance for the three and six months leading up to this date. The information is available on SEDAR, along with the Management’s...

Continue Reading
Understanding the Recent Short Interest Trends for Sun Communities

Updated Category News Views 127

Analyzing Sun Communities' Short Interest Dynamics Sun Communities (NYSE: SUI) recently reported a notable change in its short interest percentage, which has seen a decrease of 5.23% since the latest report. The data indicates that currently, there are 1.38 million shares sold short, representing 1.45% of the company’s publicly available shares for trading. This...

Continue Reading
Concentric Energy Advisors Expands Team with Industry Expert

Updated Category News Views 296

Concentric Energy Advisors Welcomes New Expertise Concentric Energy Advisors, Inc. is excited to announce a significant addition to its team. The firm proudly introduces Ms. Christine Saball as the new Assistant Vice President. Recognized for her extensive background in management consulting services for the North American energy sector, Ms. Saball brings over twenty...

Continue Reading